Drug Approval | June 13, 2025
FDA approves AbbVie’s mavyret as first and only treatment for acute hepatitis C
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
SIM0500 is a humanized trispecific antibody that targets GPRC5D, BCMA, and CD3
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
The objectives of the campaign are to raise awareness about glaucoma, its risk factors, and the importance of regular eye check-up
Subscribe To Our Newsletter & Stay Updated
